NO20054476D0 - Forbindelser for behandling av smerte - Google Patents

Forbindelser for behandling av smerte

Info

Publication number
NO20054476D0
NO20054476D0 NO20054476A NO20054476A NO20054476D0 NO 20054476 D0 NO20054476 D0 NO 20054476D0 NO 20054476 A NO20054476 A NO 20054476A NO 20054476 A NO20054476 A NO 20054476A NO 20054476 D0 NO20054476 D0 NO 20054476D0
Authority
NO
Norway
Prior art keywords
compounds
treatment
pain
formula
methoxyadenosine
Prior art date
Application number
NO20054476A
Other languages
English (en)
Other versions
NO20054476L (no
Inventor
Peter Richardson
Kevin Lee
Lisa Lione
Original Assignee
Cambridge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd
Publication of NO20054476D0 publication Critical patent/NO20054476D0/no
Publication of NO20054476L publication Critical patent/NO20054476L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NO20054476A 2003-03-07 2005-09-27 Forbindelser for behandling av smerte NO20054476L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305149.7A GB0305149D0 (en) 2003-03-07 2003-03-07 Compounds for the treatment of pain
PCT/GB2004/000935 WO2004078183A1 (en) 2003-03-07 2004-03-05 Compounds for the treatment of pain

Publications (2)

Publication Number Publication Date
NO20054476D0 true NO20054476D0 (no) 2005-09-27
NO20054476L NO20054476L (no) 2005-11-24

Family

ID=9954247

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054476A NO20054476L (no) 2003-03-07 2005-09-27 Forbindelser for behandling av smerte

Country Status (20)

Country Link
US (1) US7759321B2 (no)
EP (1) EP1603577B1 (no)
JP (1) JP2006519823A (no)
KR (1) KR20050115273A (no)
CN (1) CN100579533C (no)
AT (1) ATE401087T1 (no)
AU (1) AU2004216889B2 (no)
CA (1) CA2514098A1 (no)
CY (1) CY1108416T1 (no)
DE (1) DE602004015085D1 (no)
DK (1) DK1603577T3 (no)
ES (1) ES2310288T3 (no)
GB (1) GB0305149D0 (no)
HK (1) HK1087629A1 (no)
NO (1) NO20054476L (no)
NZ (1) NZ541521A (no)
PL (1) PL1603577T3 (no)
PT (1) PT1603577E (no)
SI (1) SI1603577T1 (no)
WO (1) WO2004078183A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
JP2007526291A (ja) * 2004-03-05 2007-09-13 ケンブリッジ・バイオテクノロジー・リミテッド アデノシン受容体アゴニスト
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN1947717B (zh) * 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
WO2008000743A2 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
WO2008000745A2 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Adenosine derivatives for the treatment of pain
RU2009102536A (ru) 2006-06-27 2010-08-10 Биовитрум Аб (Пабл) (Se) Терапевтические соединения
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
CN103342727A (zh) * 2013-07-01 2013-10-09 淮海工学院 一种2-甲氧基腺苷的合成方法
JP6440240B2 (ja) * 2014-02-19 2018-12-19 国立大学法人富山大学 末梢神経障害誘発感覚異常を改善する外用剤
CN114616230A (zh) * 2019-07-31 2022-06-10 海洋生物技术与海洋资源有限公司 黄烷类似物化合物及其在治疗慢性和急性疼痛中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792155A (fr) 1971-12-01 1973-05-30 Takeda Chemical Industries Ltd Nouveaux derives de l'adenosine et leur procede de production
JPS4861498A (no) 1971-12-01 1973-08-28
DE2359536C2 (de) * 1972-12-08 1984-08-02 Takeda Chemical Industries, Ltd., Osaka 2,6-Diaminonebularinderivate
JPS5461195A (en) * 1977-10-21 1979-05-17 Takeda Chem Ind Ltd N2-substituted phenyl-2,6-diaminonebularin
JPS5461194A (en) * 1977-10-21 1979-05-17 Takeda Chem Ind Ltd Preparation of n22substituted 2*66diaminonebularin
US4705758A (en) * 1984-06-19 1987-11-10 Warner-Lambert Company Adenosine receptor assay and kit
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
CN1147815A (zh) * 1994-05-10 1997-04-16 山道士有限公司 腺苷衍生物
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
IT1275420B (it) 1995-06-02 1997-08-05 Schering Plough S P A Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
EP1044004A1 (en) 1998-01-08 2000-10-18 The University Of Virginia Patent Foundation A2a adenosine receptor agonists in combination with a type iv phosphodiesterase inhibitors
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds

Also Published As

Publication number Publication date
NO20054476L (no) 2005-11-24
KR20050115273A (ko) 2005-12-07
PT1603577E (pt) 2008-10-23
CN1750835A (zh) 2006-03-22
SI1603577T1 (sl) 2008-12-31
EP1603577B1 (en) 2008-07-16
ES2310288T3 (es) 2009-01-01
AU2004216889B2 (en) 2009-06-11
HK1087629A1 (en) 2006-10-20
GB0305149D0 (en) 2003-04-09
CN100579533C (zh) 2010-01-13
AU2004216889A1 (en) 2004-09-16
WO2004078183A1 (en) 2004-09-16
JP2006519823A (ja) 2006-08-31
DK1603577T3 (da) 2008-11-17
CA2514098A1 (en) 2004-09-16
ATE401087T1 (de) 2008-08-15
PL1603577T3 (pl) 2009-01-30
US7759321B2 (en) 2010-07-20
NZ541521A (en) 2008-09-26
US20070066559A1 (en) 2007-03-22
DE602004015085D1 (de) 2008-08-28
CY1108416T1 (el) 2013-09-04
EP1603577A1 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
NO20054476D0 (no) Forbindelser for behandling av smerte
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
PT1365762E (pt) Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico
WO2005034952A3 (en) Isoxazole and isothiazole compounds useful in the treatment of inflammation
BRPI0416909A (pt) método de tratamento de aterosclerose
WO2007112000A3 (en) Treatment of pain
ATE369845T1 (de) Behandlung der nebenwirkungen von statinen
TW200639159A (en) Treatment of pain
HK1131145A1 (en) Heteroaryl compounds, compositions thereof, and methods of treatment therewith
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
EP1627635A3 (en) Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection
WO2006001967A3 (en) Migrastatin analogs in the treatment of cancer
WO2008033468A3 (en) Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
NO20092018L (no) Fremgangsmater for a behandle depresjon
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
MY187188A (en) Derivatives of di(phenylpropanoid) glycerol for the treatment of cancer
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
TW200508196A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders
WO2003090737A3 (en) Methods and compositions for treatment of cancer pain
WO2006124358A3 (en) Method of treating a coccidioides infection by administering an ambruticin compound

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application